Review





Similar Products

ionomycin  (InvivoGen)
95
InvivoGen ionomycin
Mice lacking VPS33B in the myeloid compartment have defective CD4 and CD8 T cell priming in response to protein immunization (A) Schematic of experimental set-up for in vivo immunizations. Mice were immunized with 50 μg of OVA and 5 μg of LPS in IFA (100 μL/mouse; hock injection). Draining Ig LNs were collected, processed, and cultured with OVA (100 μg/mL) for 72 h. (B) Representative flow plots of CD44 expression on CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-II T cells to the right. (C) Representative flow plots of Tbet expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-II T cells to the right. (D) Representative flow plots of IFNγ expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + <t>Ionomycin</t> for 6 h. Graphical quantification of % IFNγ + OT-II T cells to the right. (E) Representative flow plots of CD44 expression on CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-I T cells below. (F) Representative flow plots of Tbet expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-I T cells below. (G) Representative flow plots of IFNγ expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + Ionomycin for 6 h. Graphical quantification of % IFNγ + OT-I T cells below. (H) Graphical quantification of % granzyme B (GrzB) + expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from VPS33B WT and VPS33B ΔCSF1R IgLNs in the presence or absence of OVA (100 μg/mL) for 72 h. (I) IFNγ was quantified by ELISA from supernatants taken from total immunized LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. NP = no protein (OVA); error bars shown as mean ± SEM. n = 3 biological replicates for one independent experiment. Statistical analysis was performed by two-way ANOVA. ∗p < 0.05, ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 001 , ∗∗∗∗ p < 0.0001, n.s. = not significant.
Ionomycin, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ionomycin/pmc13223964-74-0-2?v=InvivoGen
Average 95 stars, based on 1 article reviews
ionomycin - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
ionomycin  (MedChemExpress)
95
MedChemExpress ionomycin
Mice lacking VPS33B in the myeloid compartment have defective CD4 and CD8 T cell priming in response to protein immunization (A) Schematic of experimental set-up for in vivo immunizations. Mice were immunized with 50 μg of OVA and 5 μg of LPS in IFA (100 μL/mouse; hock injection). Draining Ig LNs were collected, processed, and cultured with OVA (100 μg/mL) for 72 h. (B) Representative flow plots of CD44 expression on CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-II T cells to the right. (C) Representative flow plots of Tbet expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-II T cells to the right. (D) Representative flow plots of IFNγ expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + <t>Ionomycin</t> for 6 h. Graphical quantification of % IFNγ + OT-II T cells to the right. (E) Representative flow plots of CD44 expression on CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-I T cells below. (F) Representative flow plots of Tbet expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-I T cells below. (G) Representative flow plots of IFNγ expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + Ionomycin for 6 h. Graphical quantification of % IFNγ + OT-I T cells below. (H) Graphical quantification of % granzyme B (GrzB) + expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from VPS33B WT and VPS33B ΔCSF1R IgLNs in the presence or absence of OVA (100 μg/mL) for 72 h. (I) IFNγ was quantified by ELISA from supernatants taken from total immunized LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. NP = no protein (OVA); error bars shown as mean ± SEM. n = 3 biological replicates for one independent experiment. Statistical analysis was performed by two-way ANOVA. ∗p < 0.05, ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 001 , ∗∗∗∗ p < 0.0001, n.s. = not significant.
Ionomycin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ionomycin/medchemexpress___hy-13434?v=MedChemExpress
Average 95 stars, based on 1 article reviews
ionomycin - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
11201es03 ionomycin yeasen  (Yeasen Biotechnology)
86
Yeasen Biotechnology 11201es03 ionomycin yeasen
Mice lacking VPS33B in the myeloid compartment have defective CD4 and CD8 T cell priming in response to protein immunization (A) Schematic of experimental set-up for in vivo immunizations. Mice were immunized with 50 μg of OVA and 5 μg of LPS in IFA (100 μL/mouse; hock injection). Draining Ig LNs were collected, processed, and cultured with OVA (100 μg/mL) for 72 h. (B) Representative flow plots of CD44 expression on CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-II T cells to the right. (C) Representative flow plots of Tbet expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-II T cells to the right. (D) Representative flow plots of IFNγ expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + <t>Ionomycin</t> for 6 h. Graphical quantification of % IFNγ + OT-II T cells to the right. (E) Representative flow plots of CD44 expression on CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-I T cells below. (F) Representative flow plots of Tbet expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-I T cells below. (G) Representative flow plots of IFNγ expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + Ionomycin for 6 h. Graphical quantification of % IFNγ + OT-I T cells below. (H) Graphical quantification of % granzyme B (GrzB) + expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from VPS33B WT and VPS33B ΔCSF1R IgLNs in the presence or absence of OVA (100 μg/mL) for 72 h. (I) IFNγ was quantified by ELISA from supernatants taken from total immunized LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. NP = no protein (OVA); error bars shown as mean ± SEM. n = 3 biological replicates for one independent experiment. Statistical analysis was performed by two-way ANOVA. ∗p < 0.05, ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 001 , ∗∗∗∗ p < 0.0001, n.s. = not significant.
11201es03 Ionomycin Yeasen, supplied by Yeasen Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ionomycin/pm42285093-302-281-283?v=Yeasen+Biotechnology
Average 86 stars, based on 1 article reviews
11201es03 ionomycin yeasen - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
pma ionomycin  (Dakewe Biotech Co)
86
Dakewe Biotech Co pma ionomycin
Mice lacking VPS33B in the myeloid compartment have defective CD4 and CD8 T cell priming in response to protein immunization (A) Schematic of experimental set-up for in vivo immunizations. Mice were immunized with 50 μg of OVA and 5 μg of LPS in IFA (100 μL/mouse; hock injection). Draining Ig LNs were collected, processed, and cultured with OVA (100 μg/mL) for 72 h. (B) Representative flow plots of CD44 expression on CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-II T cells to the right. (C) Representative flow plots of Tbet expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-II T cells to the right. (D) Representative flow plots of IFNγ expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + <t>Ionomycin</t> for 6 h. Graphical quantification of % IFNγ + OT-II T cells to the right. (E) Representative flow plots of CD44 expression on CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-I T cells below. (F) Representative flow plots of Tbet expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-I T cells below. (G) Representative flow plots of IFNγ expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + Ionomycin for 6 h. Graphical quantification of % IFNγ + OT-I T cells below. (H) Graphical quantification of % granzyme B (GrzB) + expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from VPS33B WT and VPS33B ΔCSF1R IgLNs in the presence or absence of OVA (100 μg/mL) for 72 h. (I) IFNγ was quantified by ELISA from supernatants taken from total immunized LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. NP = no protein (OVA); error bars shown as mean ± SEM. n = 3 biological replicates for one independent experiment. Statistical analysis was performed by two-way ANOVA. ∗p < 0.05, ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 001 , ∗∗∗∗ p < 0.0001, n.s. = not significant.
Pma Ionomycin, supplied by Dakewe Biotech Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ionomycin/pm42236671-363-30-31?v=Dakewe+Biotech+Co
Average 86 stars, based on 1 article reviews
pma ionomycin - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
ionomycin  (Yeasen Biotechnology)
86
Yeasen Biotechnology ionomycin
Mice lacking VPS33B in the myeloid compartment have defective CD4 and CD8 T cell priming in response to protein immunization (A) Schematic of experimental set-up for in vivo immunizations. Mice were immunized with 50 μg of OVA and 5 μg of LPS in IFA (100 μL/mouse; hock injection). Draining Ig LNs were collected, processed, and cultured with OVA (100 μg/mL) for 72 h. (B) Representative flow plots of CD44 expression on CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-II T cells to the right. (C) Representative flow plots of Tbet expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-II T cells to the right. (D) Representative flow plots of IFNγ expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + <t>Ionomycin</t> for 6 h. Graphical quantification of % IFNγ + OT-II T cells to the right. (E) Representative flow plots of CD44 expression on CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-I T cells below. (F) Representative flow plots of Tbet expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-I T cells below. (G) Representative flow plots of IFNγ expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + Ionomycin for 6 h. Graphical quantification of % IFNγ + OT-I T cells below. (H) Graphical quantification of % granzyme B (GrzB) + expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from VPS33B WT and VPS33B ΔCSF1R IgLNs in the presence or absence of OVA (100 μg/mL) for 72 h. (I) IFNγ was quantified by ELISA from supernatants taken from total immunized LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. NP = no protein (OVA); error bars shown as mean ± SEM. n = 3 biological replicates for one independent experiment. Statistical analysis was performed by two-way ANOVA. ∗p < 0.05, ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 001 , ∗∗∗∗ p < 0.0001, n.s. = not significant.
Ionomycin, supplied by Yeasen Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ionomycin/10__1016_slash_j__snb__2026__140329-50-0-15?v=Yeasen+Biotechnology
Average 86 stars, based on 1 article reviews
ionomycin - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
ionomycin  (Nacalai)
86
Nacalai ionomycin
Mice lacking VPS33B in the myeloid compartment have defective CD4 and CD8 T cell priming in response to protein immunization (A) Schematic of experimental set-up for in vivo immunizations. Mice were immunized with 50 μg of OVA and 5 μg of LPS in IFA (100 μL/mouse; hock injection). Draining Ig LNs were collected, processed, and cultured with OVA (100 μg/mL) for 72 h. (B) Representative flow plots of CD44 expression on CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-II T cells to the right. (C) Representative flow plots of Tbet expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-II T cells to the right. (D) Representative flow plots of IFNγ expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + <t>Ionomycin</t> for 6 h. Graphical quantification of % IFNγ + OT-II T cells to the right. (E) Representative flow plots of CD44 expression on CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-I T cells below. (F) Representative flow plots of Tbet expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-I T cells below. (G) Representative flow plots of IFNγ expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + Ionomycin for 6 h. Graphical quantification of % IFNγ + OT-I T cells below. (H) Graphical quantification of % granzyme B (GrzB) + expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from VPS33B WT and VPS33B ΔCSF1R IgLNs in the presence or absence of OVA (100 μg/mL) for 72 h. (I) IFNγ was quantified by ELISA from supernatants taken from total immunized LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. NP = no protein (OVA); error bars shown as mean ± SEM. n = 3 biological replicates for one independent experiment. Statistical analysis was performed by two-way ANOVA. ∗p < 0.05, ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 001 , ∗∗∗∗ p < 0.0001, n.s. = not significant.
Ionomycin, supplied by Nacalai, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ionomycin/pm42108758-35-7-8?v=Nacalai
Average 86 stars, based on 1 article reviews
ionomycin - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


Mice lacking VPS33B in the myeloid compartment have defective CD4 and CD8 T cell priming in response to protein immunization (A) Schematic of experimental set-up for in vivo immunizations. Mice were immunized with 50 μg of OVA and 5 μg of LPS in IFA (100 μL/mouse; hock injection). Draining Ig LNs were collected, processed, and cultured with OVA (100 μg/mL) for 72 h. (B) Representative flow plots of CD44 expression on CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-II T cells to the right. (C) Representative flow plots of Tbet expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-II T cells to the right. (D) Representative flow plots of IFNγ expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + Ionomycin for 6 h. Graphical quantification of % IFNγ + OT-II T cells to the right. (E) Representative flow plots of CD44 expression on CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-I T cells below. (F) Representative flow plots of Tbet expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-I T cells below. (G) Representative flow plots of IFNγ expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + Ionomycin for 6 h. Graphical quantification of % IFNγ + OT-I T cells below. (H) Graphical quantification of % granzyme B (GrzB) + expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from VPS33B WT and VPS33B ΔCSF1R IgLNs in the presence or absence of OVA (100 μg/mL) for 72 h. (I) IFNγ was quantified by ELISA from supernatants taken from total immunized LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. NP = no protein (OVA); error bars shown as mean ± SEM. n = 3 biological replicates for one independent experiment. Statistical analysis was performed by two-way ANOVA. ∗p < 0.05, ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 001 , ∗∗∗∗ p < 0.0001, n.s. = not significant.

Journal: iScience

Article Title: VPS33B regulates MHC class II antigen presentation in dendritic cells to drive CD4 T cell immunity

doi: 10.1016/j.isci.2026.116052

Figure Lengend Snippet: Mice lacking VPS33B in the myeloid compartment have defective CD4 and CD8 T cell priming in response to protein immunization (A) Schematic of experimental set-up for in vivo immunizations. Mice were immunized with 50 μg of OVA and 5 μg of LPS in IFA (100 μL/mouse; hock injection). Draining Ig LNs were collected, processed, and cultured with OVA (100 μg/mL) for 72 h. (B) Representative flow plots of CD44 expression on CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-II T cells to the right. (C) Representative flow plots of Tbet expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-II T cells to the right. (D) Representative flow plots of IFNγ expression in CD4 T cells (pre-gated on live, CD90.2 + , CD4 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + Ionomycin for 6 h. Graphical quantification of % IFNγ + OT-II T cells to the right. (E) Representative flow plots of CD44 expression on CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % CD44 + OT-I T cells below. (F) Representative flow plots of Tbet expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R Ig LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Graphical quantification of % Tbet + OT-I T cells below. (G) Representative flow plots of IFNγ expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from immunized VPS33B WT and VPS33B ΔCSF1R IgLNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. Cells were rested with IL-2 for 48 h and re-stimulated with Phorbol 12-myristate 13-acetate (PMA) + Ionomycin for 6 h. Graphical quantification of % IFNγ + OT-I T cells below. (H) Graphical quantification of % granzyme B (GrzB) + expression in CD8 T cells (pre-gated on live, CD90.2 + , CD8 + ) from VPS33B WT and VPS33B ΔCSF1R IgLNs in the presence or absence of OVA (100 μg/mL) for 72 h. (I) IFNγ was quantified by ELISA from supernatants taken from total immunized LNs cultured in the presence or absence of OVA (100 μg/mL) for 72 h. NP = no protein (OVA); error bars shown as mean ± SEM. n = 3 biological replicates for one independent experiment. Statistical analysis was performed by two-way ANOVA. ∗p < 0.05, ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 001 , ∗∗∗∗ p < 0.0001, n.s. = not significant.

Article Snippet: Ionomycin , Invivogen , Cat#inh-ion.

Techniques: In Vivo, Injection, Cell Culture, Expressing, Enzyme-linked Immunosorbent Assay